False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)-Reference-Cited by-同舟云学术

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)

Published:2021-07-08 Issue:7 Volume:124 Page:1161-1165
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Mulder Evalyn E. A. P.¹²^ORCID,Stahlie Emma H. A.³^ORCID,Verver Daniëlle¹,Lemstra Clara⁴,Been Lukas B.⁴,Mooyaart Antien L.⁵,Brabander Tessa⁶,Vegt Erik⁶,Verburg Frederik A.⁶,Veldt Astrid A. M.²⁶,Verhoef Cornelis¹,Akkooi Alexander C. J.³,Grünhagen Dirk J.¹

Affiliation:

1. Department of Surgical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands

2. Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands

3. Department of Surgical Oncology Netherlands Cancer Institute – Antoni van Leeuwenhoek Amsterdam The Netherlands

4. Department of Surgical Oncology University Medical Center Groningen Groningen The Netherlands

5. Department of Pathology Erasmus MC Rotterdam The Netherlands

6. Department of Radiology & Nuclear Medicine Erasmus MC Cancer Institute Rotterdam The Netherlands

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.26607

Reference19 articles.

1. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

2. European Medicines Agency (EMA). CHMP Summary of Positive Opinion for Imlygic.http://www.ema.europa.eu. Accessed December 10 2020.

3. Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

4. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

5. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial